Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor

International Journal of Oncology

Volumn 14, Issue 3, 1999, Pages 577-584

  Zagon, Ian S ^a,b   Smith, Jill P ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Antagonist; Growth; Opioid growth factor; PANC 1 cells; Pancreatic cancer; Tissue culture; Zeta opioid receptor; Met5 enkephalin

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; GROWTH INHIBITOR; METENKEPHALIN; NARCOTIC ANTAGONIST; OPIATE PEPTIDE; TUMOR PROTEIN;

ARTICLE; AUTOCRINE EFFECT; CELL CULTURE; CELL DIFFERENTIATION; CELL DIVISION; CULTURE MEDIUM; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; PANCREAS TUMOR; PATHOLOGY; RADIOIMMUNOASSAY;

ANTIBODIES; ANTINEOPLASTIC AGENTS; AUTOCRINE COMMUNICATION; CELL DIFFERENTIATION; CELL DIVISION; CULTURE MEDIA, SERUM-FREE; ENKEPHALIN, METHIONINE; GROWTH INHIBITORS; HUMANS; NARCOTIC ANTAGONISTS; NEOPLASM PROTEINS; OPIOID PEPTIDES; PANCREATIC NEOPLASMS; RADIOIMMUNOASSAY; TUMOR CELLS, CULTURED;

EID: 0033090992     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.3.577     Document Type: Article

References (57)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 48: 6-29, 1998.
2. Kloppel G: Clinical pathology of exocrine tumors. In: Surgical Diseases of the Pancreas, 3rd edit. Howard J, Idezuki Y, Ihse I and Prinz R (eds.) William and Wilkins, Baltimore, pp467-479, 1998.
3. Ashley SW and Reber HA: Surgical management of exocrine pancreatic cancer. In: The Pancreas: Biology, Pathobiology, and Disease, 2nd Edition. Go VLW, Dimagno EP, Gardner JD, Lebenthal E, Reber HA and Scheele GA (eds.) Raven Press, New York, pp913-929, 1993.
4. Gordis L and Gold EB: Epidemiology and etiology of pancreatic cancer. In: The Pancreas: Biology, Pathobiology, and Disease, 2nd edit. Go VLW, Dimagno EP, Gardner JD, Lebenthal E, Reber HA and Scheele GA (eds.) Raven Press, New York, pp837-855, 1993.
5. Tsiotos GG and Sarr MG: Diagnosis and clinical staging of pancreatic cancer. In: Surgical Diseases of the Pancreas, 3rd edit. Howard J, Idezuki Y, Ihse I and Prinz R (eds.) William and Wilkins, Baltimore, pp497-513, 1998.
6. Regine WF, John WJ and Mohiuddin M: Current and emerging treatments for pancreatic cancer. Drugs Aging 11: 285-295, 1997.
7. Howard J: Pancreatoduodenectomy (Whipple resection) with skeletonization of vessels for cancers of the pancreas and adjacent organs. In: Surgical Diseases of the Pancreas, 3rd edit. Howard J, Idezuki Y, Ihse I and Prinz R (eds.) William and Wilkins, Baltimore, pp529-556, 1998.
8. Bramhall SR: The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis. Int J Pancreatol 23: 83-100, 1998.
9. Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ, Lillemoe KD, Pitt HA, Lin P and Cameron JL: DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 67: 151-159, 1998.
10. Trede M, Saeger HD, Schwall G and Rumstadt B: Resection of pancreatic cancer-surgical achievements. Langebecks Arch Surg 383: 121-128, 1998.
11. Raijman I and Levin B: Exocrine tumors of the pancreas. In: The Pancreas: Biology, Pathobiology, and Disease, 2nd edit. Go VLW, Dimagno EP, Gardner JD, Lebenthal E, Reber HA and Scheele GA (eds.) Raven Press, New York, pp899-912, 1993.
12. Von Hoff DD, Goodwin AL and Garcia L: Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team. Br J Cancer 78: 9-13, 1998.
13. Carmichael J: Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine. Digestion 58: 503-507, 1997.
14. Dobelbower RR and Battle JA: Radiotherapy. In: Surgical Diseases of the Pancreas, 3rd edit. Howard J, Idezuki Y, Ihse I and Prinz R (eds.) William and Wilkins, Baltimore, pp587-595, 1998.
15. Abrams RA: Role of radiation therapy in the management of the patient with pancreatic cancer. Oncology 10: 13-17, 1996.
16. Andren-Sandberg A and Backman PL: Hormonal therapy and immunotherapy. In: Surgical Diseases of the Pancreas, 3rd edit. Howard J, Idezuki Y, Ihse I and Prinz R (eds.) William and Wilkins, Baltimore, pp613-622, 1998.
17. Brand RE and Tempero MA: Pancreatic cancer. Curr Opin Oncol 10: 362-366, 1998.
18. Gansauge S, Gansauge F and Beger HG: Molecular oncology in pancreatic cancer. J Mol Med 74: 313-320, 1996.
19. Howe JR and Conlon KC: The molecular genetics of pancreatic cancer. Surg Oncol 5: 1-18, 1997.
20. Clark JW, Glicksman AS and Wanebo HJ: Systemic and adjuvant therapy for patients with pancreatic carcinoma. Cancer 78: 688-693, 1996.
21. Ahlgren JD: Chemotherapy for pancreatic carcinoma. Cancer 78: 654-663, 1996.
22. Schnall SF and MacDonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220-228, 1996.
23. Weiderpass F, Partanen T, Kaaks R, Vainio H, Porta M, Kauppinen T, Ojajarvi A, Boffetta P and Malats N: Occurrence, trends and environment etiology of pancreatic cancer. Scand J Work Environ Health 24: 165-174, 1998.
24. Kornmann M, Beger HG and Korc M: Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 17: 169-175, 1998.
25. Hahn SA and Schmiegel WH: Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion 59: 493-501, 1998.
26. Ishiwata T, Friess H, Buchler MW, Lopez ME and Korc M: Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. Am J Pathol 153: 213-222, 1998.
27. McCormick CSF and Lemoine NR: Molecular biology: diagnostic and therapeutic potentials. In: Surgical Diseases of the Pancreas, 3rd edit. Howard J, Idezuki Y, Ihse I and Prinz R (eds.) William and Wilkins, Baltimore, pp439-448, 1998.
28. Liu N, Furukawa T, Kobari M and Tsao MS: Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol 153: 263-269, 1998.
29. Lemoine NR: Molecular advances in pancreatic cancer. Digestion 58: 550-556, 1997.
30. Korc M: Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7: 25-41, 1998.
31. Hruban RH, Petersen GM, Ha PK and Kern SE: Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 7: 1-23, 1998.
32. Alexander RW, Upp JR, Poston GJ, Townsend CM and Thompson JC: Bombesin inhibits growth of human pancreatic adenocarcinoma in nude mice. Pancreas 3: 297-302, 1988.
33. Barton CM, Hall PA, Hughes CM, Gullick WJ and Lemoine NR: Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 163: 111-116, 1991.
34. Korc M, Chandrasekar B and Shah GN: Differential binding and biological activities of epidermal growth factor and transforming growth factor α in a human pancreatic cancer cell line. Cancer Res 51: 6243-6249, 1991.
35. Schmiegel W, Roeder C, Schmielau J, Rodeck U and Kalthoff H: Tumor necrosis factor α and the epidermal growth factor receptor in human pancreatic cells. Proc Natl Acad Sci USA 90: 863-867, 1993.
36. Smith JP, Shih A, Wu Y, McLaughlin PJ and Zagon IS: Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. Am J Physiol 270: R1078-R1084, 1996.
37. Satoh K, Shimosegawa T, Hirota M, Koizumi M and Toyota T: Expression of tranforming growth factor β1 (TGFβ1) and its receptors in pancreatic ductal carcinoma and in chronic pancreatitis. Pancreas 16: 468-474, 1998.
38. Ohta T, Numata M, Tsukioka Y, Futagami F, Kayahara M, Kitagawa H, Nagakawa T, Yamamoto M, Wakayama T, Kitamura Y, Terada T and Nakanuma Y: Neurotropin-3 expression in human pancreatic cancers. J Pathol 181: 405-412, 1997.
39. Freeman JW, Mattingly CA and Strodel WE: Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. J Cell Physiol 165: 155-163, 1995.
40. Barg J, Belcheva M, McHale R, Levy R, Vogel Z and Coscia CJ: β-endorphin is a potent inhibitor of thymidine incorporation into DNA via μ- and κ-opioid receptors in fetal rat brain cell aggregates in culture. J Neurochem 60: 765-767, 1993.
41. Bartolome JV, Bartolome MB, Lorber BA, Dileo SJ and Schanberg SM: Effects of central administration of beta-endorphin on brain and liver DNA-synthesis in preweanling rats. Neuroscience 40: 289-294, 1991.
42. Meriney SD, Ford MJ, Oliva D and Pilar G: Endogenous opioids modulate neuronal survival in the developing avian ciliary ganglion. J Neurosci 11: 3705-3717, 1991.
43. Murgo AJ: Inhibition of B16-BL6 melanoma growth in mice by methionine enkephalin. J Natl Cancer Inst 75: 341-344, 1985.
44. Zagon IS and McLaughlin PJ: Naltrexone modulates tumor response in mice with neuroblastoma. Science 221: 671-673, 1983.
45. Zagon IS, Hytrek SD and McLaughlin PJ: Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 271: R511-R518, 1996.
46. 5]-enkephalin prevents the incidence and retards the growth of human colon cancer. Am J Physiol 271: R780-R786, 1996.
47. Zagon IS, Hytrek SD, Smith JP and McLaughlin PJ: Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Cancer Lett 112: 167-175, 1997.
48. Zagon IS and McLaughlin PJ: Endogenous opioid systems, stress, and cancer. In: Enkephalins-Endorphins: Stress and the Immune System. Plotnikoff NP, Murgo AJ, Faith RE and Good RA (eds). Plenum, New York, pp81-100, 1986.
49. Zagon IS and McLaughlin PJ: The role of endogenous opioids and opioid receptors in human and animal cancers. In: Stress and Immunity. Plotnikoff NP, Murgo AJ, Faith RE and Wybran J (eds). CRC, Caldwell, NJ, pp343-356, 1991.
50. Zagon IS and McLaughlin PJ: Opioid growth factor receptor in the developing nervous system. In: Receptors in the Developing Nervous System. Vol. 1. Growth Factors and Hormones. Zagon IS and McLaughlin PJ (eds). Chapman and Hall, London, pp39-62, 1993.
51. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M and Todaro G: Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15: 741-747, 1975.
52. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, Pickren JW, Berjian R, Douglass HO and Chu TM: Characterization of a new primary human pancreatic tumor line. Cancer Invest 4: 15-23, 1986.
53. Yunis AA, Arimura GK and Russin DJ: Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19: 128-135, 1977.
54. Kyriazis A, Kyriazis AA, Scarpelli DG, Fogh J, Rao S and Lepera R: Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse. Am J Pathol 106: 250-260, 1982.
55. 5]-enkephalin, and the ζ (zeta) opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis. J Invest Dermatol 106: 490-497, 1996.
56. Oates PS and Morgan GH: Pancreatic growth and cell turnover in the rat fed raw soya flour. Am J Pathol 108: 217-224, 1982.
57. Elsasser H-P, Adler G and Kern HF: Replication and regeneration of the pancreas. In: The Pancreas: Biology, Pathobiology, and Disease, 2nd Edition. Go VLW, Dimagno EP, Gardner JD, Lebenthal E, Reber HA and Scheele GA (eds.) Raven Press, New York, pp75-86, 1993.